本帖最后由 老马 于 2012-1-13 21:20 编辑
& e* @/ @. i$ P. I7 ~
; ] `' M ]% U4 q: }; ?' M: b& q爱必妥和阿瓦斯丁的比较# e- `1 N, y8 u& e; E1 u
2 z2 j8 M; \: {: ^8 \: C5 ihttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- ^6 y- E3 d- K4 @8 @/ p
+ y W7 J, d$ X" s) @6 w% [" t9 U7 ]
! [. v& L7 _' ~ u! J; B! d4 ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 p8 r7 @7 g4 k j9 j
==================================================
( G8 r1 q3 J2 L& XOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% F; m' \* b z/ ?7 m# r0 u8 ]2 q1 H% T
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ j0 h1 |* D6 I' c
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 ]( Y! r+ E: w8 a5 M6 w
|